Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/BVG5d6tio2A/230286.php
Monday, July 4, 2011
Novartis Receives FDA Approval For Arcapta? Neohaler?, A Novel Once-daily Bronchodilator For Chronic Obstructive Pulmonary Disease
Novartis announced that the US Food and Drug Administration (FDA) has approved once-daily Arcapta? Neohaler? (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta is not indicated for acute deteriorations of COPD or to treat asthma...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment